Dr. Reddy’s gets FDA nod for generic Aggrenox
Dr. Reddy’s Laboratories has received the okay from the Food and Drug Administration for aspirin and extended-release dipyridamole capsules.
The product is a generic version of Boehringer Ingelheim’s Aggrenox (aspirin and extended-release dipyridamole) capsules.
Aggrenox is indicated for the prevention of stroke following an initial first stroke, or transient ischaemic attacks (TIA).
The Aggrenox brand and generic had a market value of approximately $183 million for the most recent 12 months ending in August 2018, according to IQVIA data.
Dr. Reddy’s aspirin and extended-release dipyridamole capsules is available in 25 mg/200 mg strength with a 60 count bottle size.
The product is a generic version of Boehringer Ingelheim’s Aggrenox (aspirin and extended-release dipyridamole) capsules.
Aggrenox is indicated for the prevention of stroke following an initial first stroke, or transient ischaemic attacks (TIA).
The Aggrenox brand and generic had a market value of approximately $183 million for the most recent 12 months ending in August 2018, according to IQVIA data.
Dr. Reddy’s aspirin and extended-release dipyridamole capsules is available in 25 mg/200 mg strength with a 60 count bottle size.